UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Metastasis | Kinases | Evidence-based medicine | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2020, Volume 382, Issue 1, pp. 41 - 50
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Female | Lung Neoplasms - genetics | ErbB Receptors - antagonists & inhibitors | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Gefitinib - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - therapeutic use | Acrylamides - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Aniline Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Tyrosine | Cell survival | Statistical analysis | Epidermal growth factor receptors | Small cell lung carcinoma | Non-small cell lung carcinoma | Metastasis | Gene deletion | Confidence intervals | Epidermal growth factor | Clonal deletion | Clinical medicine | Gefitinib | Protein-tyrosine kinase | Drug dosages | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Etoposide - administration & dosage | Lung Neoplasms - pathology | Male | Survival Rate | Small Cell Lung Carcinoma - drug therapy | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Small Cell Lung Carcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Adult | Camptothecin - administration & dosage | Female | Aged | Neoplasm Staging | Camptothecin - analogs & derivatives | Medical colleges | Care and treatment | Relapse | Chemotherapy | Lung cancer | Etoposide | Respiratory agents | Product development | College teachers | Diseases | Cancer | Index Medicus
Journal Article
Cancer science, ISSN 1347-9032, 09/2019, Volume 110, Issue 9, pp. 2884 - 2893
EGFR mutation | non‐small‐cell lung cancer | tyrosine kinase inhibitor | acquired resistance | osimertinib | Life Sciences & Biomedicine | Oncology | Science & Technology | Japan - epidemiology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Diarrhea - epidemiology | Lung Neoplasms - pathology | Lung Diseases, Interstitial - chemically induced | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Paronychia - epidemiology | Antineoplastic Agents - adverse effects | Exanthema - chemically induced | Aged, 80 and over | Adult | Aniline Compounds - administration & dosage | Lung Diseases, Interstitial - epidemiology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Paronychia - chemically induced | ErbB Receptors - antagonists & inhibitors | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Survival Rate | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Exanthema - epidemiology | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Progression-Free Survival | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Drug Resistance, Neoplasm - drug effects | Tyrosine | Medical research | Chemotherapy | Analysis | Medicine, Experimental | Development and progression | Respiratory tract diseases | Lung cancer, Non-small cell | Cancer | Epidermal growth factor receptors | Research funding | Lung cancer | Lung diseases | Clinical trials | Diarrhea | Non-small cell lung carcinoma | Cancer therapies | Studies | Epidermal growth factor | Platinum | Skin | Mutation | Safety | Protein-tyrosine kinase | Pharmaceuticals | Index Medicus | Original
Journal Article
Cancer science, ISSN 1347-9032, 01/2019, Volume 110, Issue 1, pp. 345 - 355
cancer | 3D culture | high throughput screening | heterogeneity | organoid | Life Sciences & Biomedicine | Oncology | Science & Technology | Cell Survival - drug effects | Drug Screening Assays, Antitumor - methods | Organoids - pathology | Colorectal Neoplasms - genetics | Humans | Spheroids, Cellular - metabolism | Spheroids, Cellular - pathology | Cell Survival - genetics | Mice, SCID | Xenograft Model Antitumor Assays - methods | Whole Exome Sequencing | Animals | Organoids - metabolism | Organoids - drug effects | Cell Line, Tumor | Mice, Inbred NOD | Antineoplastic Agents - pharmacology | Spheroids, Cellular - drug effects | Colorectal Neoplasms - pathology | High-Throughput Screening Assays - methods | Drugs | Research & development--R&D | Colorectal carcinoma | Innovations | Genomes | Drug screening | Drug development | Patients | Experiments | Spheroids | Organoids | Precision medicine | Morphology | Xenografts | Life sciences | Genetic testing | Deoxyribonucleic acid--DNA | Cancer | Tumors | Index Medicus | Original
Journal Article
BMC cancer, ISSN 1471-2407, 12/2010, Volume 10, Issue 1, pp. 690 - 690
Life Sciences & Biomedicine | Oncology | Science & Technology | Metabolomics | Predictive Value of Tests | Amino Acids - blood | Prognosis | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - diagnosis | Chromatography, High Pressure Liquid | Mass Screening - methods | Case-Control Studies | Young Adult | Spectrometry, Mass, Electrospray Ionization | Aged, 80 and over | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Reproducibility of Results | Japan | Logistic Models | Biomarkers, Tumor - blood | Carcinoma, Non-Small-Cell Lung - blood | ROC Curve | Aged | Lung Neoplasms - blood | Lung Neoplasms - diagnosis | Analysis | Amino acids | Diagnosis | Research | Lung cancer, Non-small cell | Methods | Cancer | Index Medicus
Journal Article
The Annals of thoracic surgery, ISSN 0003-4975, 2016, Volume 101, Issue 2, pp. 504 - 511
Surgery | Cardiothoracic Surgery | Cardiac & Cardiovascular Systems | Respiratory System | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Japan - epidemiology | Carcinoma, Non-Small-Cell Lung - surgery | Prospective Studies | Survival Rate - trends | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Tomography, X-Ray Computed | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - diagnosis | Carcinoma, Non-Small-Cell Lung - mortality | Propensity Score | Pneumonectomy - methods | Time Factors | Female | Lung Neoplasms - surgery | Aged | Lung Neoplasms - diagnosis | Neoplasm Staging | Lung cancer, Non-small cell | Lung cancer, Small cell | Index Medicus | Abridged Index Medicus
Journal Article
Cancer science, ISSN 1347-9032, 03/2016, Volume 107, Issue 3, pp. 353 - 358
lung cancer | Carcinoembryonic antigen | epidermal growth factor receptor tyrosine kinase inhibitor | massively parallel DNA sequencer | circulating tumor DNA | Epidermal growth factor receptor tyrosine kinase inhibitor | Massively parallel DNA sequencer | Lung cancer | Circulating tumor DNA | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Mutation, Missense | Biomarkers, Tumor - blood | DNA, Neoplasm - blood | DNA Mutational Analysis | Protein Kinase Inhibitors - therapeutic use | Aged, 80 and over | Female | Aged | Antineoplastic Agents - pharmacology | Biomarkers, Tumor - genetics | Lung Neoplasms - blood | Protein Kinase Inhibitors - pharmacology | DNA, Neoplasm - genetics | Tyrosine | Development and progression | Epidermal growth factor | Multiprocessing | Analysis | DNA | Phenols | Genetic research | Genetic aspects | Nucleotide sequencing | CEA (Oncology) | Cancer | DNA sequencing | Plasma | Disease | Laboratories | Cytotoxicity | Gene deletion | Kinases | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Subpopulations | Nucleotide sequence | Epidermal growth factor receptors | Invasiveness | Patients | Studies | Genotyping | Biopsy | Mutation | Genetic testing | Cytotoxic agents | Tumors | Index Medicus | Original
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 09/2008, Volume 26, Issue 26, pp. 4244 - 4252
Life Sciences & Biomedicine | Oncology | Science & Technology | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Tumors | Pneumology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Proportional Hazards Models | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Taxoids - therapeutic use | Quinazolines - therapeutic use | Survival Analysis | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Index Medicus
Journal Article
International journal of hematology, ISSN 0925-5710, 7/2016, Volume 104, Issue 1, pp. 99 - 109
Clinical trials | Oncology | Chemotherapy | Medicine & Public Health | Hematology | Langerhans cell histiocytosis | Life Sciences & Biomedicine | Science & Technology | Histiocytosis, Langerhans-Cell - mortality | Prednisolone - administration & dosage | Humans | Child, Preschool | Clinical Protocols - standards | Treatment Outcome | Cytarabine - administration & dosage | Multiple Organ Failure | Disease-Free Survival | Drug Therapy, Combination - methods | Time Factors | Adolescent | Cyclosporine - administration & dosage | Vincristine - administration & dosage | Remission Induction - methods | Child | Histiocytosis, Langerhans-Cell - drug therapy | Care and treatment | Corticosteroids | Histiocytosis | Patient outcomes | Prednisolone | Steroids | Index Medicus
Journal Article